Soluble B-Cell Maturation Antigen As a Disease Biomarker in Relapsed or Refractory Multiple Myeloma (RRMM): Evaluation from Elranatamab (ELRA) Magnetismm Studies

被引：5
|
作者：
Elmeliegy, Mohamed [1 ]
Lon, Hoi Kei [1 ]
Wang, Diane [1 ]
Ma, Wei An [1 ]
King, Lindsay [2 ]
Viqueira, Andrea [3 ]
Czibere, Akos [2 ]
机构：
[1] Pfizer, San Diego, CA USA
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer SLU, Madrid 28108, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3
    Larson, Sarah Marie
    Bahlis, Nizar J.
    Maisel, Christopher
    Karlin, Lionel
    Yanovsky, Asya Varshavsky
    Leip, Eric
    Sullivan, Sharon T.
    Viqueira, Andrea
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Levy, Moshe
    Bahlis, Nizar
    Raje, Noopur
    Costello, Caitlin
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Tomasson, Michael
    Dube, Harman
    Damore, Michael
    Lon, Hoi Kei
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
  • [23] The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
    Alomari, Mohammed
    Kunacheewa, Chutima
    Manasanch, Elisabet E.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 261 - 272
  • [24] Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery
    Smit, Jennifer
    Goldberg, Jenna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S39 - S40
  • [25] Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma
    Guo, Pei
    Wang, Yun
    He, Haiyan
    Chen, Dongjian
    Liu, Jin
    Qiang, Wanting
    Lu, Jing
    Liang, Yang
    Du, Juan
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2024, 217 (03): : 221 - 232
  • [26] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander
    Raza, Muhammed
    Acosta, Jorge
    Mueller, Patrick Y.
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
  • [27] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
    Lesokhin, Alexander M.
    Raza, Muhammed Saleem
    Acosta, Jorge
    Muller, Patrick
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    Service, Myeloma
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
    Dholaria, Bhagirathbhai
    Bahlis, Nizar
    Raje, Noopur
    Costello, Caitlin
    Solh, Melhem
    Levy, Moshe
    Tomasson, Michael
    Dube, Harman
    Damore, Michael
    Lon, Hoi Kei
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S17
  • [29] B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
    Abramson, Hanley N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 24
  • [30] Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
    Hoeynck, Brian
    Hwang, Wei-Ting
    Garfall, Alfred L.
    Susanibar-Adaniya, Sandra Patricia
    Vogl, Dan T.
    Waxman, Adam
    Stadtmauer, Edward A.
    Cohen, Adam D.
    BLOOD, 2022, 140 : 10081 - 10083
12345